<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00085163</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-40023</org_study_id>
    <secondary_id>EORTC-40023</secondary_id>
    <secondary_id>PETACC-5</secondary_id>
    <nct_id>NCT00085163</nct_id>
  </id_info>
  <brief_title>Celecoxib Combined With Fluorouracil and Leucovorin in Treating Patients With Resected Stage III Adenocarcinoma (Cancer) of the Colon</brief_title>
  <official_title>Multicenter, Double-Blind, Placebo-Controlled Randomized Phase III Study of Adjuvant Therapy With Celecoxib in Combination With Chemotherapy in Patients With Curatively Resected Stage III Colon Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Colorectal Cancer Group (DCCG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arbeitsgemeinschaft fur Internistische Onkologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Onkologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Egyptian Foundation For Cancer Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>EORTC GI Group (EORTC 40023)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GCCD-APIO - Grupo Cooperativo do Cancro Digestivo da Associação Portuguesa de Investigação</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oncológica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GOCCI - Gruppo Oncologico Chirurgico Cooperativo Italiano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GOIRC - Gruppo Oncologico Italiano di Ricerca Clinica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SG - Scandinavian Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>TTD - Grupo Español para el Tratamiento de Tumores Digestivos</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as fluorouracil and leucovorin, work in different&#xD;
      ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the&#xD;
      growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known&#xD;
      whether fluorouracil and leucovorin are more effective with or without celecoxib in treating&#xD;
      resected stage III adenocarcinoma (cancer) of the colon.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying celecoxib, fluorouracil, and leucovorin&#xD;
      to see how well they work compared to fluorouracil and leucovorin in treating patients who&#xD;
      have undergone surgery for stage III colon cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare disease-free survival of patients with curatively resected stage III&#xD;
           adenocarcinoma of the colon treated with adjuvant fluorouracil and leucovorin calcium&#xD;
           with or without celecoxib.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the overall survival, the occurrence of new primary colon cancer, and the&#xD;
           development of new polyps in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients&#xD;
      are stratified according to ≥ 4 tumor-positive lymph nodes (yes vs no), form of adjuvant&#xD;
      chemotherapy (infusional vs bolus), low-dose aspirin for cardiovascular prophylaxis (yes vs&#xD;
      no), and participating center. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive fluorouracil and leucovorin calcium IV for up to 6 courses in&#xD;
           the absence of disease recurrence or unacceptable toxicity. Patients also receive oral&#xD;
           celecoxib twice daily.&#xD;
&#xD;
        -  Arm II: Patients receive oral placebo twice daily and fluorouracil and leucovorin&#xD;
           calcium as in arm I.&#xD;
&#xD;
      In both arms, treatment with celecoxib or placebo continues for 3 years in the absence of&#xD;
      disease recurrence or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed annually for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 1,450 patients (725 per treatment arm) will be accrued for this&#xD;
      study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival as measured by Logrank every 3 months in year 1, every 6 months in years 2-3, and annually thereafter</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival as measured by Logrank every 3 months in year 1, every 6 months in years 2-3, and annually thereafter</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time occurrence of new primary colon cancer and new polyps as measured by Logrank every 3 months in year 1, every 6 months in years 2-3, and annually thereafter</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as measured by CTC AE version 2.0 every 3 months in year 1, every 6 months in years 2-3, and annually thereafter</measure>
  </secondary_outcome>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the colon&#xD;
&#xD;
               -  15 cm above anal verge&#xD;
&#xD;
               -  Stage III disease (any pT, N1-2, M0)&#xD;
&#xD;
          -  No rectal cancer&#xD;
&#xD;
          -  Must have undergone curative radical resection (R0 resection) within the past 6 weeks&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST ≤ 5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  None of the following conditions within the past 6 months:&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Serious uncontrolled cardiac arrhythmia&#xD;
&#xD;
               -  Cerebrovascular accident or transient ischemic attack&#xD;
&#xD;
               -  Deep vein thrombosis&#xD;
&#xD;
               -  Other significant thromboembolic event&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No pulmonary embolism within the past 6 months&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No active gastric or duodenal ulceration within the past year&#xD;
&#xD;
          -  No gastrointestinal bleeding within the past year&#xD;
&#xD;
          -  No partial or complete bowel obstruction&#xD;
&#xD;
          -  No known chronic malabsorption&#xD;
&#xD;
          -  No active inflammatory bowel disease or chronic diarrhea (more than 4 stools/day)&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No AIDS-related illness&#xD;
&#xD;
          -  No prior hypersensitivity to fluorouracil, leucovorin calcium, celecoxib, other COX-2&#xD;
             inhibitors, NSAIDs, salicylates, or sulfonamides&#xD;
&#xD;
          -  No other severe acute or chronic medical condition or laboratory abnormality that&#xD;
             would preclude study participation, study drug administration, or study results&#xD;
             interpretation&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude study compliance&#xD;
&#xD;
          -  No concurrent active infection&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated carcinoma in&#xD;
             situ of the cervix or basal cell or squamous cell skin cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent sargramostim (GM-CSF) or molgramostim&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No more than 4 weeks of concurrent orally/nasally inhaled steroids over a 6-month&#xD;
             period&#xD;
&#xD;
               -  Concurrent mometasone (or fluticasone) allowed if patients require ≥ 4 weeks of&#xD;
                  inhaled steroid therapy&#xD;
&#xD;
          -  At least 30 days since other prior steroids&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior total colectomy or other major surgery that would result in substantial&#xD;
             alteration in transit to absorption of oral medication&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 30 days since prior investigational medication&#xD;
&#xD;
          -  No prior systemic anticancer treatment for colon cancer&#xD;
&#xD;
          -  No concurrent prophylactic fluconazole&#xD;
&#xD;
          -  No concurrent lithium&#xD;
&#xD;
          -  No concurrent chronic* use of full dose aspirin, nonsteroidal anti-inflammatory drugs&#xD;
             (NSAIDs), or cyclo-oxygenase-2 (COX-2) inhibitors&#xD;
&#xD;
               -  Aspirin at cardioprotective doses (i.e., 80 mg daily or equivalent) allowed&#xD;
&#xD;
          -  No concurrent participation in any other clinical study&#xD;
&#xD;
          -  No other concurrent experimental agents (e.g., other COX-2 inhibitors, matrix&#xD;
             metalloproteinase inhibitors, inhibitors of the vascular endothelial growth&#xD;
             factor/Flk-1 pathway, or inhibitors of the epidermal growth factor receptor pathway)&#xD;
             NOTE: *Chronic use is defined as a frequency of 7 consecutive days (1 week) for more&#xD;
             than 3 weeks/year or more than 21 days throughout the year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cornelis J.H. van de Velde, MD, PhD, FRCS, FRCPS</last_name>
    <role>Study Chair</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dirk J. Richel, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michel Ducreux, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karl-Franzens-University Graz</name>
      <address>
        <city>Graz</city>
        <zip>A-8010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innsbruck Universitaetsklinik</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Linz Donau</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Elisabethinen</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landeskrankenanstalten - Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus der Stadt Wien</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus</name>
      <address>
        <city>Wiener Neustadt</city>
        <zip>2700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Netwerk Antwerpen Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <zip>B-2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de Jolimont</name>
      <address>
        <city>Haine Saint Paul</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Liege - Domaine Universitaire du Sart Tilman</name>
      <address>
        <city>Liege</city>
        <zip>B-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth Ziekenhuis</name>
      <address>
        <city>Turnhout</city>
        <zip>2300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Haaglanden</name>
      <address>
        <city>'s-Gravenhage</city>
        <zip>2501 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>'s-Hertogenbosch</city>
        <zip>5211 NL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1091 HA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum at University of Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gelre Ziekenhuizen - Lokatie Lukas</name>
      <address>
        <city>Apeldoorn</city>
        <zip>7334 DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <zip>6800 TA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Lievensberg</name>
      <address>
        <city>Bergen-op-Zoom</city>
        <zip>4624 VT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deventer Ziekenhuisen</name>
      <address>
        <city>Deventer</city>
        <zip>7415 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <zip>5602 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <zip>7500 KA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis St Jansdal</name>
      <address>
        <city>Harderwijk</city>
        <zip>3840 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nijmegen Cancer Center at Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waterlandziekenhuis</name>
      <address>
        <city>Purmerend</city>
        <zip>1440 AG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daniel Den Hoed Cancer Center at Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3008 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC - Sophia Children's Hospital</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ikazia Ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <zip>NL-3083</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schieland Ziekenhuis</name>
      <address>
        <city>Schiedam</city>
        <zip>NL-3116</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis de Honte</name>
      <address>
        <city>Terneuzen</city>
        <zip>NL-4535</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Streekziekenhuis Koningin Beatrix</name>
      <address>
        <city>Winterswyk</city>
        <zip>7101 BN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken - locatie Weezenlanden</name>
      <address>
        <city>Zwolle</city>
        <zip>NL-8000 GM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>October 19, 2015</last_update_submitted>
  <last_update_submitted_qc>October 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>stage III colon cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

